Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 15/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30977713 | 0.97 | TLR2 (0.36) | TLR2 | |
| SCHEMBL30837988 | 0.96 | TLR2 (0.37) | TLR2PPARG | |
| SCHEMBL30837935 | 0.96 | TLR2 (0.37) | TLR2PPARG | |
| SCHEMBL30837984 | 0.96 | TLR2 (0.37) | TLR2PPARG | |
| SCHEMBL30842639 | 0.93 | TLR2 (0.37) | TLR2PPARG | |
| SCHEMBL30842641 | 0.92 | TLR2 (0.40) | TLR2 | |
| SCHEMBL30977700 | 0.91 | KLK7 (0.32) | TLR2PPARG | |
| SCHEMBL30837999 | 0.90 | TLR2 (0.35) | TLR2 | |
| SCHEMBL30977768 | 0.89 | CHRM2 (0.32) | PPARG | |
| SCHEMBL30838049 | 0.88 | TLR2 (0.40) | TLR2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398977-A1 | SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS | NANOVATION THERAPEUTICS INC. (CA) | 2024-12-05 | — | — | US | disclosed |
| US-12121591-B2 | Sulfur-containing ionizable lipids for the delivery of nucleic acids and other therapeutic agents | NANOVATION THERAPEUTICS INC. (CA) | 2024-10-22 | — | — | US | disclosed |
| US-20240261430-A1 | SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS | NANOVATION THERAPEUTICS INC. (CA) | 2024-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12121591-B2 | Sulfur-containing ionizable lipids for the delivery of nucleic acids and other therapeutic agents | SLC43A1, NSUN3, NSUN2 | TLR2 3615/4885PPARG 1346/4885 |
| US-20240261430-A1 | SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS | SLC43A1, NSUN3, NSUN2 | TLR2 3615/4885PPARG 1346/4885 |
| US-20240398977-A1 | SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS AND OTHER THERAPEUTIC AGENTS | SLC43A1, NSUN3, NSUN2 | TLR2 3615/4885PPARG 1346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.